Excessive activation of TLR may induce endotoxin shock and inflammatory diseases, so the negative regulation of TLR-triggered inflammatory response attracts much attention. Nonpathogenic immune complex (IC) and Ig (IC/Ig) have been shown to play important roles in the regulation of immune responses and to be therapeutic in some kinds of autoimmune diseases. However, the role of IC/Ig in the regulation of TLR-triggered inflammatory responses and the underlying mechanisms remain to be fully understood. In this study we demonstrate that IC/Ig can significantly inhibit LPS-induced secretion of TNF-␣ and IL-6 from macrophages by preferentially inducing PGE 2 . Pretreatment of mice with IC can protect wild-type mice, but not Fc␥RIIb ؊/؊
U pon recognizing microbial conserved pathogen-associated molecule patterns such as LPS, TLRs activate immune cells to produce proinflammatory cytokines such as TNF-␣, IL-1, IL-6, and type I IFN to initiate immune responses (1) . Although full responses to TLR agonists is necessary for elimination of invading pathogens, excessive responses to TLR agonists may induce endotoxin shock and immunopathological conditions such as autoimmune diseases. Therefore, TLR-triggered inflammatory responses need to be controlled to an appropriate level, benefiting host to eliminate pathogens but not causing tissue damage. Accordingly, negative regulation of TLR response attracts much attention in recent years (2) . Now, a number of signaling mechanisms for the negative regulation of TLR4 response have been proposed, for example, transcriptional induction of soluble TLR4 (3), negative regulators such as IL-1 receptor-associated kinase mutants (4) and suppressor of cytokine signaling (SOCS) 4 1 (5), recruitment of SHIP, or Src homology protein phosphatases (6, 7) , ligation of PECAM-1 (8) , and induction of antiinflammatory cytokines, mainly IL-10 (9) and TGF-␤ (10) . Compared with the release of proinflammatory mediators, which occurs rapidly after TLR stimulation, induction of these negative regulators is relatively slower. Thus, prophylactic ways to avoid or alleviate TLR4-triggered overactivation of immune cells such as macrophages and the subsequent inflammatory responses or even lethal shock need to be investigated.
APCs including macrophages and dendritic cells express many kinds of Fc␥R. The balance between the activating and inhibitory Fc␥R contributes to determine the threshold of immune cell activation. For example, cross-linking Fc␥RIIa (CD32a) by aggregated IgG induces phosphorylation of a cytoplasmic ITAM motif, whereas coligation of Fc␥RIIb (CD32b) bearing a cytoplasmic ITIM will initiate tyrosine phosphorylation of the ITIM that inhibits ITAM-mediated events (11) . Ligands of Fc␥R by physiological Ig or immune complex (IC) or some pathological IC are potential stimuli for the immune cells that express activating or inhibitory Fc␥R (12) . Upon IC and Ig (IC/Ig) binding to Fc␥R the net outcome of activation or control of immune cell functions is determined by the relative strength of the activating and inhibitory receptors expressed on a given cell type (13) . Administration of i.v. Ig (IVIg) has been demonstrated to be remarkably effective in the treatment of immune thrombocytopenic purpura as well as other autoimmune diseases through binding of the inhibitory Fc␥RIIb (14 -16) . The active components in IVIg including the dominant species of monomeric IgG, which bind FcRn and the high-affinity Fc␥RI, and multiple types of IC, which bind all Fc receptors, are likely to form in vivo after the administration of IVIg. For IC in IVIg, the protective role of small-sized IC has been found to be Fc␥RIIb-dependent (17) . Interaction between Ig or nonpathogenic soluble IC and Fc␥RIIb has been shown to control several aspects of immune responses and to contribute to the prevention of autoimmunity development (18 -20) . However, what is the role of IC in the regulation of TLR-triggered inflammatory responses and what are the underlying mechanisms remain to be addressed?
The primary aim of this study is to investigate the effects of nonpathogenic Ig (anti-OVA mAb) or soluble IC (composed of OVA Ag and anti-OVA mAb) on the LPS-induced production of proinflammatory cytokines both in vitro and in vivo. We demonstrate that IC/Ig can negatively regulate TLR4-triggered inflammatory response in macrophages by inhibiting NF-B activation and TLR4 expression through Fc␥RIIb-dependent PGE 2 , thus protecting mice from lethal endotoxic sepsis. Our results outline a new way for the negative regulation of TLR4-triggered inflammatory responses in macrophages, and also we provide new mechanistic explanation of the therapeutic effect of nonpathogenic IC/Ig on the inflammatory and autoimmune diseases.
Materials and Methods

Mice and cell line
C57BL/6J mice were obtained from Joint Ventures Sipper BK Experimental Animal. Fc␥RIIb Ϫ/Ϫ mice in C57BL/6J background were obtained from The Jackson Laboratory. All mice were maintained under specific pathogen-free conditions and used at 6 -8 wk of age. RAW264.7 macrophage cell line was obtained from the American Type Culture Collection and maintained in RPMI 1640 complete medium (PAA Laboratories) supplemented with 10% FCS (PAA Laboratories).
Preparation of IC
Soluble IC was prepared as previously described (21) . Briefly, OVA stock (Sigma-Aldrich) was prepared using PBS to 10 mg/ml, and then 50 g of OVA was incubated with 500 g mouse-derived anti-OVA mAb (IgG1; Sigma-Aldrich) for 1 h at 37°C to obtain anti-OVA IC. For in vitro experiments, unless other mentioned, IC (OVA/anti-OVA mAb) was used at a final concentration of 10 g/ml OVA plus 100 g/ml anti-OVA mAb throughout the experiments. For in vivo experiments, IC (OVA and anti-OVA) was used at 100 g of OVA plus 1 mg of anti-OVA mAb per mouse. Endotoxin contamination in OVA and anti-OVA reagent was measured using Limulus amebocyte lysate (ZhanJiang A&C Biological), and the level of endotoxin in 10 g of OVA plus 100 g of anti-OVA mAb was lower than 0.03 EU.
Preparation and treatment of macrophages
Mouse primary peritoneal macrophages and bone marrow-derived macrophages (BMDM) were prepared and cultured as previously described (22) . Briefly, 1 ϫ 10 6 /ml of bone marrow cells flushed from femurs and tibias were cultured on 24-well plates in the presence of 30 ng/ml M-CSF (R&D Systems). At day 2, suspended cells were deleted by washing with RPMI 1640 medium, and the resulting adherent cells were cultured for another 5 days in the presence of 30 ng/ml M-CSF. A total of 3 ϫ 10 5 /ml RAW264.7 macrophages, peritoneal macrophages, and BMDM were stimulated with IC or Ig for 24 h, respectively, then the IC/Ig-pretreated macrophages were stimulated with or without 100 ng/ml LPS (Escherichia coli O127:B8; Sigma-Aldrich) for another 24 h. The supernatants were collected for ELISA of proinflammatory cytokines. In some experiments, 10 M celecoxib, celecoxib plus exogenous 50 M PGE 2 , or 10 M protein kinase A (PKA) inhibitor (adenosine 3Ј,5Ј-cyclic phosphorothioate-Rp; Calbiochem) were used to pretreat macrophages 30 min before treatment with IC or Ig. The dose of celecoxib at 10 M was selected on the basis of pilot experiments in which celecoxib at 10 M significantly inhibited the production of PGE 2 but had no obvious toxicity to macrophages. PGE 2 was dissolved with 100% ethanol.
ELISA measurement
TNF-␣, IL-6, and PGE 2 levels in serum and macrophage culture supernatants were measured by ELISA kits according to the manufacturer's instructions. ELISA kits for TNF-␣ and IL-6 were obtained from R&D Systems and ELISA kit for PGE 2 was from Cayman Chemical.
Flow cytometry
Peritoneal macrophages were stimulated as indicated, and then stained with PE anti-TLR4 or PE isotype Ig in combination with allophycocyanin antiCD11b (BD Pharmingen) after blocking with 30% mouse serum. The expression of TLR4 was detected on CD11b ϩ macrophages by FACS LSR II (BD Biosciences).
Western blot assay
Peritoneal macrophages were stimulated as indicated, then lysed with Cytoplasma Protein Extraction Reagent (Pierce) supplemented with Protease Inhibitor Cocktail. After centrifugation at 13,000 ϫ g at 4°C for 15 min, the supernatants were collected and protein concentrations were measured using the BCA protein assay (Pierce) according to the manufacturer's instructions. For detection of NF-B activation, nuclear extracts of peritoneal macrophages were isolated using NE-PER Extraction kit (Pierce). Equal amounts of protein (30 g) were resolved on a 12% SDS-PAGE, and then Western blot was performed as previously described (22) . Briefly, after electrophoresis, proteins were transferred to nitrocellulose membrane, and then blocked with TBS containing 5% nonfat dry milk for 1 h. Membranes were then probed with primary Ab anti-cyclooxygenase (COX)1, anti-COX2, NF-B, actin, or lamin AC (Santa Cruz Biotechnology) at 1/1000 overnight. After washing three times, blots were incubated with HRP-conjugated secondary Ab at 1/5000 for 1 h. Immunoreactivity was detected using the ECL Western blot detection kit (Pierce).
IC injection and endotoxin shock
The 5-wk-old wild-type (WT) mice or Fc␥RIIb Ϫ/Ϫ mice were i.v. injected with OVA/anti-OVA mAb IC for 24 h before i.p. administration of 1 g of LPS plus 10 mg of GalN (Sigma-Aldrich). In some experiments, 10 mg/kg celecoxib was administrated 1 h before IC administration. Blood samples were taken 1 h after LPS injection and then assayed for serum TNF-␣ and IL-6 concentrations. Survival rate was monitored for 4 days.
Statistical analysis
Statistical significance was determined by Student's t test, with a value of p Ͻ 0.05 considered to be statistically significant.
Results
IC/Ig inhibit LPS-induced production of proinflammatory cytokines from macrophages
First, we observed the effect of IC or Ig on LPS-induced production of proinflammatory cytokines in macrophages. We incubated RAW264.7 cells, peritoneal macrophages, or BMDM with IC or Ig, respectively, for 24 h, and then stimulated with LPS for another 24 h. Consistent with other reports, we found that IC or Ig alone can significantly induce the production of TNF-␣ and IL-6 from macrophages, respectively, and LPS alone could significantly induce production of TNF-␣ and IL-6 from macrophages ( Fig. 1) . In contrast, after we pretreated macrophages with OVA and anti-OVA mAb ICs for 24 h, we found that LPS-induced production of TNF-␣ and IL-6 from RAW264.7 cells (Fig. 1A) , peritoneal macrophages (Fig. 1B) , and BMDM ( Fig. 1C ) was significantly inhibited. Furthermore, pretreatment of macrophages with Ig (anti-OVA mAb) also significantly inhibited the production of TNF-␣ and IL-6 from peritoneal macrophages in response to LPS. Therefore, these results indicated that pretreatment of macrophages with IC or Ig can significantly suppress LPS-induced proinflammatory cytokine production in macrophages.
IC/Ig stimulate PGE 2 production from macrophages in dose-and time-dependent manners by inducing COX1 and COX2 expression
Next, we further investigated the underlying mechanism for the suppression of LPS-mediated inflammatory cytokines by IC or Ig.
To know which factors were involved in IC/Ig-mediated inhibition of TNF-␣ and IL-6 production from LPS-stimulated macrophages, we measured the levels of factors including IL-10, TGF-␤, and PGE 2 in IC/Ig-stimulated macrophages. All of these factors have been reported to exert inhibitory roles in LPS-stimulated macrophages (9, 10, 23). IC could not induce obvious production of IL-10 and TGF-␤ from macrophages (data not shown), but IC could rapidly induce a large amount of PGE 2 production from macrophages ( Fig. 2A) . Moreover, IC induced PGE 2 production from macrophages in a dose-dependent manner ( Fig. 2A ) and timedependent manner (Fig. 2B) . PGE 2 was induced as early as 30 min, and its secretion increased to peak at 12-24 h, and then decreased at 48 h after IC treatment. Similar to IC, Ig (anti-OVA mAb) alone could induce comparable amounts of PGE 2 from peritoneal macrophages (Fig. 2C) . Because COX1 and COX2 are two critical molecules for PGE 2 synthesis (24), we detected the expression of COX1 and COX2 in IC or Ig-stimulated peritoneal macrophages. As shown in Fig. 2D , IC or Ig rapidly induced the expression of COX1 and COX2 in peritoneal macrophages, suggesting that the inducible expression of COX1 and COX2 by IC or Ig was responsible for PGE 2 production. Thus, IC or Ig can induce large amount of PGE 2 production from macrophages in dose-and time-dependent manners by inducing COX1 and COX2 expression.
Preferential induction of PGE 2 is responsible for the suppression of LPS-stimulated proinflammatory cytokine production by IC
It has been reported that proinflammatory stimuli, such as LPS or TNF-␣, can stimulate macrophages to produce PGE 2 for feedback negative regulation of inflammatory responses (25, 26) , so we observed whether LPS could affect IC-induced PGE 2 production. We incubated peritoneal macrophages with IC, LPS, or IC plus LPS for 12 h and found that LPS alone could induce PGE 2 produced from macrophages. However, the amount of PGE 2 from LPS-stimulated macrophages was far less than the amount of PGE 2 from IC-treated macrophages (Fig. 3A) . Moreover, LPS had no obvious synergistic effect on IC-mediated PGE 2 production (Fig. 3A) . To further confirm whether PGE 2 was responsible for IC-mediated suppression of proinflammatory cytokine production from LPSstimulated macrophages, we examined the induction of TNF-␣ and IL-6 from PGE 2 -pretreated macrophages by LPS. We incubated peritoneal macrophages with PGE 2 for 24 h and then stimulated such macrophages with LPS for another 24 h. We found that PGE 2 pretreatment significantly inhibited the production of TNF-␣ from macrophages in response to LPS, but PGE 2 alone had no suppressive effect on the production of TNF-␣ from untreated peritoneal macrophages (Fig. 3B) . PGE 2 pretreatment significantly inhibited the production of IL-6 from macrophages in response to LPS, but PGE 2 alone significantly stimulated IL-6 production from macrophages (Fig. 3B) . So PGE 2 pretreatment can inhibit LPS-induced FIGURE 1. IC/Ig inhibits LPS-induced proinflammatory cytokine production from macrophages. RAW264.7 cells (A), peritoneal macrophages (B), and BMDM (C) at 3 ϫ 10 5 /ml were pretreated with IC (containing 10 g/ml OVA plus 100 g/ml anti-OVA mAb) for 24 h. Cells were then stimulated with or without 100 ng/ml LPS for another 24 h. Peritoneal macrophages at 3 ϫ 10 5 /ml were pretreated with Ig (anti-OVA mAb) at 100 g/ml for 24 h, and then stimulated with or without 100 ng/ml LPS for another 24 h (D). The supernatants were collected for ELISA of TNF-␣ and IL-6. Data shown are mean Ϯ SEM of three independent experiments. ‫,ءء‬ p Ͻ 0.01 as compared with group without IC or Ig treatment. FIGURE 2. IC/Ig induces large amount of PGE 2 production from macrophages in dose-and time-dependent manners via inducing the expression of COX1 and COX2. A, Peritoneal macrophages at 3 ϫ 10 5 /ml were treated with OVA/anti-OVA IC at indicated concentrations for 24 h. PGE 2 levels in the supernatants were measured with ELISA. Data shown are mean Ϯ SEM of three independent experiments. B, Peritoneal macrophages at 3 ϫ 10 5 /ml were treated with OVA/anti-OVA IC (10 g/ml OVA to 100 g/ml anti-OVA ratio) for indicated time. PGE 2 levels in the supernatants were measured with ELISA. Data shown are mean Ϯ SEM of three independent experiments. C, Peritoneal macrophages at 3 ϫ 10 5 /ml were treated with Ig (anti-OVA mAb) at 100 g/ml for 12 h, and PGE 2 in the supernatants was measured with ELISA. Data shown are mean Ϯ SEM of three independent experiments. D, Peritoneal macrophages at 3 ϫ 10 5 /ml were incubated with a ratio of 10:100 g/ml OVA/anti-OVA IC for indicated time, and then the expression of COX1 and COX2 was detected by Western Blot. The result was representative of three independent experiments.
TNF-␣ and IL-6 from macrophages. Next, we preincubated peritoneal macrophages with celecoxib, an inhibitor of COX2 used to inhibit PGE 2 production (27), 30 min before IC stimulation. We observed the effect of IC on the TNF-␣ and IL-6 production from LPS-stimulated macrophages. As shown in Fig. 3C , IC-mediated suppression of TNF-␣ and IL-6 production from LPS-stimulated macrophages was abrogated in the presence of celecoxib. Furthermore, when exogenous PGE 2 was added back into this system, FIGURE 3. IC inhibits LPS-induced proinflammatory cytokine production in macrophages through PGE 2 . A, Peritoneal macrophages at 3 ϫ 10 5 /ml were preincubated with a ratio of 10:100 g/ml OVA/anti-OVA IC for 24 h before stimulation with 100 ng/ml LPS for another 24 h. PGE 2 levels in the supernatants were measured with ELISA. Data shown are mean Ϯ SEM of three independent experiments. ‫,ءء‬ p Ͻ 0.01. B, Peritoneal macrophages at 3 ϫ 10 5 /ml were pretreated with exogenous PGE 2 (50 M) for 24 h, and stimulated with LPS for another 24 h. The production of TNF-␣ and IL-6 in the supernatants was measured with ELISA. Data shown are mean Ϯ SEM of three independent experiments. ‫,ءء‬ p Ͻ 0.01. C, Peritoneal macrophages at 3 ϫ 10 5 /ml were pretreated with 10 M celecoxib or together with exogenous PGE 2 (50 M) 30 min before stimulation with IC. After 24 h, LPS at 100 ng/ml was used to stimulate macrophages for another 24 h. The production of TNF-␣ and IL-6 in the supernatants was measured with ELISA. Data shown are mean Ϯ SEM of three independent experiments. ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01.
FIGURE 4.
IC inhibits proinflammatory cytokine production from LPS-stimulated macrophages via Fc␥RIIb-dependent PGE 2 induction. A, Peritoneal macrophages from Fc␥RIIb Ϫ/Ϫ or WT mice at 3 ϫ 10 5 /ml were preincubated at a ratio of 10:100 g/ml OVA/anti-OVA IC or 100 g/ml Ig (anti-OVA Ab) for 24 h, and then stimulated with 100 ng/ml LPS for another 24 h. The levels of TNF-␣ and IL-6 in the supernatants were measured with ELISA. Data shown are mean Ϯ SEM of three independent experiments. ‫,ءء‬ p Ͻ 0.01. B, Peritoneal macrophages from Fc␥RIIb Ϫ/Ϫ or WT mice at 3 ϫ 10 5 /ml were stimulated with a ratio of 10:100 g/ml OVA/anti-OVA IC or 100 g/ml Ig (anti-OVA Ab) for 24 h, and PGE 2 in the supernatants were measured with ELISA. Data shown are mean Ϯ SEM of three independent experiments. ‫,ءء‬ p Ͻ 0.01. C, Peritoneal macrophages from Fc␥RIIb Ϫ/Ϫ at 3 ϫ 10 5 /ml were stimulated at a ratio of 10:100 g/ml OVA/anti-OVA IC for 15, 30, and 45 min and 6, 12, and 24 h. Peritoneal macrophages from WT mice at 3 ϫ 10 5 /ml were stimulated for 6, 12, and 24 h. Then the expression of COX1 and COX2 was detected by Western blot. Data are representative of three independent experiments. IC-mediated suppression of LPS-induced TNF-␣ but not IL-6 production was restored. Thus, these data indicated that IC pretreatment inhibits LPS-induced proinflammatory cytokine production from macrophages via induction of PGE 2 production.
Fc␥RIIb-dependent PGE 2 induction is responsible for the suppressive effect of IC/Ig on LPS-triggered proinflammatory cytokine production
It has been well-established that Fc␥RIIb plays a critical role in negative regulation of immune responses (18) and IC can bind to Fc␥RIIb to exert its biological activities (17) . We then wondered whether Fc␥RIIb was responsible for IC/Ig-mediated suppression of LPS-induced proinflammatory cytokine production. So, we observed the production of TNF-␣ and IL-6 from LPS-stimulated Fc␥RIIb Ϫ/Ϫ peritoneal macrophages pretreated with or without IC or Ig. As shown in Fig. 4A , IC/Ig alone could not induce comparable amounts of TNF-␣ and IL-6 from Fc␥RIIb Ϫ/Ϫ peritoneal macrophages as compared with that of WT macrophages. Interestingly, IC or Ig pretreatment lost their inhibitory effect on LPS-induced production of TNF-␣ and IL-6 when Fc␥RIIb Ϫ/Ϫ peritoneal macrophages were used (Fig. 4A) . In contrast to the induction of PGE 2 and COX expression in WT macrophages, IC or Ig could not induce obvious production of PGE 2 (Fig. 4B ) or much expression of COX1 and COX2 (Fig. 4C) in Fc␥RIIb Ϫ/Ϫ peritoneal macrophages, indicating that IC-or Iginduced production of PGE 2 is dependent on Fc␥RIIb. The data indicate that Fc␥RIIb is responsible for IC-or Ig-mediated production of PGE 2 which, in turn, inhibits LPS-induced proinflammatory cytokine production in macrophages.
In vivo administration of IC protects mice from lethal endotoxin shock through Fc␥RIIb-dependent induction of PGE 2
As demonstrated, IC could inhibit proinflammatory cytokines from LPS-stimulated macrophages in vitro. To confirm the in vivo suppressive effect of IC on LPS-induced inflammatory response, we investigated whether in vivo administration of IC could protect mice from lethal endotoxin shock by LPS, C57BL/6 mice were injected with or without IC for 24 h before challenged with lethal dose of LPS. As shown in Fig. 5A , mice receiving lethal dose of LPS all died within subsequent 24 h. However, all of mice receiving IC pretreatment could survive from lethal endotoxin shock by LPS, indicating that IC can protect mice from LPS-mediated lethal shock. When mice were administrated with celecoxib 30 min before IC injection, all mice could not survive from subsequent lethal endotoxin shock by LPS challenge within 24 h (Fig. 5A) . Accordingly, we detected serum levels of TNF-␣ and IL-6 in these groups of mice after LPS challenge for 1 h. As compared with the group of mice receiving lethal dose of LPS alone, the levels of serum TNF-␣ and IL-6 were significantly reduced in the group of LPS challenged mice receiving IC pretreatment. However, there was no obvious difference in the serum TNF-␣ and IL-6 levels between the mice receiving celecoxib plus IC pretreatment and the mice receiving celecoxib pretreatment (Fig. 5B and see Supplementary data). 5 The data suggest that that IC protects mice from LPSinduced lethal shock via PGE 2 -dependent inhibition of TNF-␣ and IL-6 production.
To further confirm whether Fc␥RIIb-mediated PGE 2 was responsible for IC-mediated protection in vivo, we observed the survival and levels of TNF-␣ and IL-6 in sera of Fc␥RIIb Ϫ/Ϫ mice receiving pretreatment with IC and then lethal dose of LPS challenge. As shown in Fig. 5C , in contrast to WT mice, all Fc␥RIIb Ϫ/Ϫ mice receiving IC pretreatment died within 24 h after LPS injection. Moreover, after 1 h of in vivo lethal dose of LPS challenge, TNF-␣ and IL-6 levels in sera of Fc␥RIIb Ϫ/Ϫ mice receiving IC pretreatment were similar to cytokine levels in Fc␥RIIb Ϫ/Ϫ mice without IC pretreatment (Fig. 5D) . Therefore, these data indicate that IC protects mice from LPS-induced lethal shock via Fc␥RIIb-dependent PGE 2 production in vivo.
Fc␥RIIb-dependent PGE 2 attenuates LPS-activated NF-B in macrophages stimulated with IC/Ig
To further investigate the mechanisms by which IC/Ig suppress LPS-induced inflammatory response in macrophages, we first 5 The online version of this article contains supplemental material. 5 /ml) from WT mice were incubated with 100 g/ml Ig (anti-OVA mAb), or IC (ratio of 10: 100 g/ml OVA/anti-OVA mAb) or PGE 2 24 h before stimulation with 100 ng/ml LPS for another 30 min. The nuclear translocation of NF-B was measured using Western blot. Results are representative of three independent experiments. B and C, IC/Ig down-regulate TLR4 expression on peritoneal macrophages in PGE 2 /Fc␥RIIb-dependent manner. Peritoneal macrophages (3 ϫ 10 5 /ml) from WT or Fc␥RIIb Ϫ/Ϫ mice were incubated with celecoxib (10 M) or celecoxib plus exogenous PGE 2 (50 M) for 30 min before stimulation with Ig (100 g/ml anti-OVA mAb) or IC (ratio of 10:100 g/ml OVA/ anti-OVA) for another 24 h, and then the expression of TLR4 on macrophages was measured using FACS. Macrophages were gated as CD11b LPS-induced NF-B activation by IC/Ig. Importantly, exogenous PGE 2 pretreatment significantly inhibited LPS-induced nuclear translocation of NF-B in WT macrophages, and especially in Fc␥RIIb Ϫ/Ϫ macrophages. These data indicate that IC/Ig pretreatment attenuates LPS-induced NF-B activation through Fc␥RIIb-dependent PGE 2 .
IC/Ig down-regulates TLR4 expression on macrophages via Fc␥RIIb-dependent PGE 2
Furthermore, we analyzed the effect of IC or Ig on TLR4 expression on macrophages. We found that Fc␥RIIb Ϫ/Ϫ CD11b ϩ macrophages had a lower background level of TLR4 expression than WT CD11b ϩ macrophages, and that IC or Ig treatment could down-regulate TLR4 expression on CD11b ϩ macrophages derived from WT but not from Fc␥RIIb Ϫ/Ϫ macrophages (Fig. 6, B and C) . To delete the possibility that no down-regulation of TLR4 on Fc␥RIIb Ϫ/Ϫ macrophages by IC/Ig was due to the low background of TLR4 expression, we treated WT or Fc␥RIIb Ϫ/Ϫ macrophages with PGE 2 , and found that a significant reduction of TLR4 expression could be observed in both WT macrophages and Fc␥RIIb Ϫ/Ϫ macrophages, suggesting that Fc␥RIIb-dependent PGE 2 was responsible for the down-regulation of TLR4 by IC/Ig (Fig. 6, B and  C) . Furthermore, blockage of PGE 2 production with celecoxib could restore TLR4 expression on IC or Ig-treated macrophages. When exogenous PGE 2 was added together with celecoxib, the expression of TLR4 was significantly down-regulated on IC or Ig-treated macrophages (Fig. 6, B and C) . So, IC/Ig may downregulate TLR4 expression on macrophages via Fc␥RIIb-dependent PGE 2 .
Activation of PKA pathway is involved in the down-regulation of TLR4 expression on macrophages by IC/Ig
It has been reported that PGE 2 can increase the intracellular cAMP level, leading to the activation of PKA pathway (28) . Therefore, to investigate whether activation of PKA pathway is responsible for the down-regulation TLR4 expression by IC, we incubated macrophages with PKA inhibitor 30 min before stimulation with IC or PGE 2 . After 24 h of incubation, we found that blockage of PKA pathway counteracted the down-regulation of TLR4 expression on IC or PGE 2 -treated macrophages (Fig. 6D) . Therefore, these results demonstrate that the activation of PKA pathway is involved in the down-regulation of TLR4 expression on macrophages by IC/Ig-induced Fc␥RIIb-dependent PGE 2 production.
Discussion
The major finding of this study is that IC or Ig negatively regulates TLR4-triggered inflammatory responses in macrophages through PGE 2 induction via its interaction with Fc␥RIIb. IC/Ig pretreatment significantly reduces the production of proinflammatory cytokines, including TNF-␣ and IL-6, from macrophages by LPS and protects mice from lethal endotoxin shock. Fc␥RIIb-dependent PGE 2 production is responsible for the down-regulation of TLR4 expression on macrophages, and activation of PKA pathway is involved in the process, thus contributing to the desensitization of macrophages to LPS stimulation. These results suggest that nonpathogenic IC/Ig in circulation may play an important role in the control of inflammatory responses, and i.v. transfusion of IC/Ig may be therapeutically useful for the treatment, or as a prophylactic way, of inflammatory responses and autoimmune diseases.
To investigate the mechanisms underlying the negative regulation of TLR4 response by IC/Ig, we first measured the production of several negative regulatory factors, including IL-10, TGF-␤, IDO, PGE 2 . However, IL-10, TGF-␤, and IDO were not obviously produced in IC/Ig-stimulated macrophages, except PGE 2 . As one of products of arachidonic acid metabolism, PGE 2 has been demonstrated by several studies to act on several types of cells such as monocytes, macrophages, neutrophils, and pulmonary epithelial cells and suppress their cellular activities, including chemotaxis, oxidized metabolite production, leukotriene B 4 production, and LPS-stimulated TNF-␣ and NO production (24, 29) . PGE 2 synthesis is relied on intracellular COX including COX1 and COX2, which possess both fatty acid COX activity and PG hydroperoxidase activity. Although, IC/Ig-mediated the production of PGE 2 has been reported by several times (30, 31) , we were still amazed by the amount of PGE 2 by IC/Ig. Next, we demonstrated that IC/Ig induced the rapid and durative expression of COX1 and COX2 in macrophages, which may account for the reason why so large amounts of PGE 2 was induced. Furthermore, we provided convincing data that the interaction of IC/Ig with Fc␥RIIb was necessary for the expression of COX1 and COX2. Therefore, our study provides a novel mechanism underlying the negative role played by Fc␥RIIb in immune response and inflammation. Some other studies also provide evidence that the protective role of IVIg requires CSF-1-dependent macrophages and Fc␥RIIb expression to mediate its as-yet-undefined anti-inflammatory effect (32) . So, at a certain extents, confirm our study that small-size IC and Ig can be used to not only control autoimmune responses but also attenuate inflammatory responses. It remains to be investigated in the future for the signal pathway of Fc␥RIIb-dependent COX1 and COX2 expression in macrophages.
Although IC/Ig alone, to less degree, has a direct stimulatory effect on the proinflammatory cytokine production from macrophages, the durative and mass production of PGE 2 by IC/Ig overcomes its stimulatory activity and also potently suppresses macrophages to be further activated by TLR4 agonist. Therefore, natural Ig and nonpathogenic IC in the circulation possibly play a critical protective role in the potential inflammatory response. IC/Ig induces macrophages to produce large amounts of PGE 2 strictly in a dose-dependent manner. Therefore, induction of large amount of PGE 2 by high dosage of IC/Ig and the inhibition of PGE 2 on macrophages in response inflammatory stimuli give a reasonable explanation for IVIg preparations used in clinical practice in the treatment of inflammatory diseases or autoimmune disease, such as thrombocytopenic purpura, autoimmune neuropathies, systemic lupus erythematosus, myasthenia gravis, GuillainBarré syndrome, skin blistering syndromes, and Kawasaki disease.
The inhibition of TNF-␣ production by PGE 2 is mediated by cell surface receptors, EP2 and EP4, via increasing intracellular cAMP (28) . The inhibition of TLR4 expression by IC/Ig-mediated PGE 2 is another novel finding in our experiments. The decreased expression of TLR4 is partially responsible for the decreased nuclear translocation of NF-B and the decreased response to LPS stimulation. However, there must be some unknown mechanisms underlying the inhibition of PGE 2 on TLR4 pathway because we found that most macrophages after PGE 2 treatment still expressed TLR4 only at a reduced level. We tried to investigate whether some inhibitory signal molecules, for example SOCS1, contribute to the down-regulation of TLR4 on macrophages by IC/Ig. It has been reported that SOCS1 suppresses NF-B activation by mediating Mal degradation (33) , and inhibits the production of IL-6 from LPS-stimulated macrophages by regulating JAK-STAT (34) . However, we did not observe the increased expression of SOCS1 in macrophages by IC/Ig (data not shown), suggesting that SOCS1 was not involved in the process. Next, we investigated the role of PKA pathway in the down-regulation of TLR4 expreesion by IC/Ig or PGE 2 . The inhibitory role of PKA pathway in TLR response has also been reported by other studies. For example, cAMP-dependent PKA pathway is capable of selectively suppressing the activation of BCR-or TLR4-dependent NF-B pathway in B cells by blocking phosphorylation and subsequent degradation of the inhibitor of NF-B (35) . As expected, we found that blockage of PKA pathway counteracted the down-regulation of TLR4 expression by IC or PGE 2 , suggesting that TLR4 down-regulation was a downstream event to PGE 2 -induced increase of intracellular cAMP. Therefore, we can propose such a working model that IC/Ig mediates the production of PGE 2 via Fc␥RIIb, and then PGE 2 increases the level of intracellular cAMP to induce the activation of PKA pathway, which reduces the expression of TLR4 expression on macrophages. Our data provide a new point for the negative regulation of TLR4 response by PKA.
In our study, we found that Fc␥RIIb Ϫ/Ϫ macrophages had a lower background level of TLR4 expression, which was not described before. However, the response of Fc␥RIIb Ϫ/Ϫ macrophages to LPS stimulation was not significantly reduced as compared with WT macrophages, because Fc␥RIIb Ϫ/Ϫ macrophages produced similar levels of proinflammatory cytokines as WT macrophages after LPS stimulation. Importantly, Fc␥RIIb Ϫ/Ϫ mice exhibited similar sensitivity as WT mice to lethal LPS challenge. Therefore, although the level of TLR4 expression is lower on Fc␥RIIb Ϫ/Ϫ macrophages than that on WT macrophages, the level of TLR4 expression may be enough for Fc␥RIIb Ϫ/Ϫ macrophages to be responsive to LPS stimulation.
Macrophages in our system are prepared different from M2b macrophages that are induced by exposure to IC in combination with LPS or IL-1␤ (36) . In contrast to M1 macrophages, M2 macrophages are in general more prone to immunoregulatory and protumoral activities. Considering the low response of IC/Ig-treated macrophages to LPS, it is worth to be determined whether macrophages exposure to high dosage of IC in our system have similar characteristic of M2b macrophages, especially regulatory function. In contrast, it is important to investigate whether simultaneous exposure to IC and LPS would induce macrophages to produce PGE 2 as exposure to IC before LPS used in our system. If so, it is interesting to investigate whether the immunoregulatory role by M2b macrophages is dependent on PGE 2 production.
In summary, in this study we have provided novel insights for the mechanisms underlying the negative regulation of TLR4-triggered inflammatory responses by small-size soluble IC/Ig. Attenuation of NF-B activation and down-regulation of TLR4 expression via activating PKA pathway by Fc␥RIIb-dependent PGE 2 may contribute to the suppressive effect of IC/Ig. In addition to Fc␥RIIb, DAP12, FcR␥ chain, and CD32a have also been reported by other studies to exert negative regulatory roles in TLR4 response (37, 38) , indicating that these physiologically natural IC/Ig may play a critical role in the maintenance of immune homeostasis. Therefore, our results and others outline new mechanistic explanation for clinical administration of IVIg for prevention from serious inflammation or treatment of autoimmune diseases.
